Novo Nordisk announced a collaboration with Anthropic to deploy Claude Science across specific R&D workflows, aiming to speed up drug discovery and development. The companies said they will identify R&D bottlenecks and use Anthropic’s models to improve scientific reasoning in development processes, while also strengthening software development across the organization. The agreement follows a series of AI partnerships across large pharma, with Novo framing the initiative as an effort to make R&D more agentic and to scale AI usage through frontier models. Novo did not disclose financial terms. The move matters for biotech execution teams because it highlights a shift from using AI for isolated tasks toward integrating models into operational pipelines—while still raising the practical question of guardrails and reliability for downstream decision-making.